Literature DB >> 17080915

Outcome of pregnancies complicated by systemic sclerosis and mixed connective tissue disease.

L Chung1, R L R Flyckt, I Colón, A A Shah, M Druzin, E F Chakravarty.   

Abstract

Systemic sclerosis (SSc) and mixed connective tissue disease (MCTD) are rare autoimmune diseases which share the common feature of non-inflammatory vasculopathy. Studies evaluating pregnancy outcomes in these patients have yielded conflicting results. We sought to describe the outcomes of pregnancies associated with SSc and MCTD followed at our center utilizing a retrospective review of all pregnant women with SSc and MCTD followed at Stanford University from 1993 to 2003. We identified 20 pregnancies occurring in 13 women with SSc or MCTD. Twelve pregnancies occurred in seven women with SSc and eight pregnancies occurred in six women with MCTD. The overall preterm delivery rate was 39% and small for gestational age infants occurred in 50% and 63% of pregnancies associated with SSc and MCTD, respectively. Fetal loss complicated two pregnancies in women with severe diffuse SSc and the antiphospholipid antibody syndrome. There were no cases of congenital heartblock among infants, and only one case of pre-eclampsia was observed. Maternal flares of disease during pregnancy were generally mild. Most pregnancies in women with SSc and MCTD in this cohort were uncomplicated. The high rates of prematurity and small for gestational age infants underscore the risk for growth restriction consistent with the vasculopathy associated with these diseases.

Entities:  

Mesh:

Year:  2006        PMID: 17080915     DOI: 10.1177/0961203306071915

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  11 in total

Review 1.  Does the immune system induce labor? Lessons from preterm deliveries in women with autoimmune diseases.

Authors:  Norbert Gleicher
Journal:  Clin Rev Allergy Immunol       Date:  2010-12       Impact factor: 8.667

2.  Neonatal punctate calcifications associated with maternal mixed connective tissue disorder (MCTD).

Authors:  Aakash Pandita; Astha Panghal; Girish Gupta; Vijay Singh
Journal:  BMJ Case Rep       Date:  2018-10-12

3.  Serum adenosine deaminase activity is increased in systemic lupus erythematosus patients and correlated with disease activity.

Authors:  Zhao-Wei Gao; Guan-Hua Zhao; Zhe Zhang; Jing Huang; Zi-Yue Li; Hui-Zhong Zhang; Ke Dong
Journal:  Immunol Res       Date:  2018-04       Impact factor: 2.829

4.  Pregnancy outcomes in systemic sclerosis, primary pulmonary hypertension, and sickle cell disease.

Authors:  Eliza F Chakravarty; Dinesh Khanna; Lorinda Chung
Journal:  Obstet Gynecol       Date:  2008-04       Impact factor: 7.661

Review 5.  [Systemic sclerosis and pregnancy. A review of the current literature].

Authors:  A Németh; S Szamosi; A Horváth; J Schönherr; E Nicksch; Z Szekanecz; G Szűcs
Journal:  Z Rheumatol       Date:  2014-03       Impact factor: 1.372

6.  Mixed connective tissue disease in pregnancy: A case series and systematic literature review.

Authors:  Marie-Lou Tardif; Michèle Mahone
Journal:  Obstet Med       Date:  2018-09-19

7.  Pre-disease pregnancy complications and systemic sclerosis: pathogenic or pre-clinical?

Authors:  Eliza Chakravarty
Journal:  Arthritis Res Ther       Date:  2012-02-06       Impact factor: 5.156

8.  Vascular Complications of Systemic Sclerosis during Pregnancy.

Authors:  Eliza F Chakravarty
Journal:  Int J Rheumatol       Date:  2010-08-11

9.  Increased Rates of Obstetric Complications Prior to Systemic Sclerosis Diagnosis.

Authors:  Melody P Chung; Kathleen D Kolstad; Makdine Dontsi; Debbie Postlethwaite; Poonam Manwani; Hongyu Zhao; Sumana Kesh; Julia F Simard; Lorinda Chung
Journal:  Arthritis Care Res (Hoboken)       Date:  2022-03-22       Impact factor: 5.178

Review 10.  Management of pregnancy with diffuse cutaneous systemic sclerosis: a case report and literature review.

Authors:  Lingyun Yang; Weiwei Sun; Qiang Yao
Journal:  J Int Med Res       Date:  2021-11       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.